NCT00334711已完成不适用
A Prospective Study of Sulfonylureas in Patients With Diabetes Due to Kir6.2 Mutations
Royal Devon and Exeter NHS Foundation Trust0 个研究点目标入组 50 人开始时间: 2004年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 主要终点
- HbA1c reduction
研究概览
简要总结
The purpose of this study is to investigate whether patients with diabetes due to Kir6.2 mutations can be treated with sulfonylurea medication rather than insulin, and if this is the case to investigate the mechanism for sulfonylurea response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes due to KCNJ11 (Kir6.2) mutation
排除标准
- 未提供
结局指标
主要结局
HbA1c reduction
次要结局
- insulin secretory response to intravenous glucose
- insulin secretory response to oral glucose
- insulin secretory response to mixed meal (sustacal)
- Incidence of Hypoglycemia
研究者
相似试验
已完成
2 期
Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes MellitusDiabetes MellitusNCT00610038Assistance Publique - Hôpitaux de Paris19
终止
4 期
Variation in Sulphonylurea Response in Type 2 DiabetesDiabetes Mellitus, Type 2NCT00738088NHS Tayside14
终止
3 期
MK0767 and Sulfonylurea Combination Study (0767-027)Diabetes Mellitus, Type 2NCT00543491Merck Sharp & Dohme LLC129
已完成
2 期
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a SulfonylureaDiabetes MellitusNCT00036192Astellas Pharma Inc200
已完成
4 期
Seroquel on Glucose MetabolismSchizophreniaNCT00214578AstraZeneca572